Trials / Unknown
UnknownNCT03509831
[KJ-INT-002] BE Study
A Randomized, Open-label, Crossover Clinical Study to Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 After Oral Administration to Healthy Adult Male Subjects
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Kukje Pharma · Academic / Other
- Sex
- Male
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 after Oral Administration to Healthy Adult Male Subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INT-2150 | 1. Period: INT-2150 2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg |
| DRUG | Irsogladine maleate 2 mg+Nizatidine 150 mg | 1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg 2. Period: INT-2150 |
Timeline
- Start date
- 2017-11-02
- Primary completion
- 2018-01-24
- Completion
- 2018-04-01
- First posted
- 2018-04-26
- Last updated
- 2018-04-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03509831. Inclusion in this directory is not an endorsement.